HDAC9 promotes glioblastoma growth via TAZ-mediated EGFR pathway activation

Rui Yang; Yanan Wu; Mei Wang; Zhongfeng Sun; Jiahua Zou; Yundong Zhang; Hongjuan Cui

doi:10.18632/oncotarget.3223

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

HDAC9 promotes glioblastoma growth via TAZ-mediated EGFR pathway activation

Rui Yang _, Yanan Wu, Mei Wang, Zhongfeng Sun, Jiahua Zou, Yundong Zhang and Hongjuan Cui

PDF | HTML | How to cite

Oncotarget. 2015; 6:7644-7656. https://doi.org/10.18632/oncotarget.3223

Metrics: PDF 2290 views | HTML 3112 views | ?

Abstract

Rui Yang1, Yanan Wu1, Mei Wang1, Zhongfeng Sun1, Jiahua Zou1, Yundong Zhang2, Hongjuan Cui1

1State Key Laboratory of Silkworm Genome Biology, Southwest University, Chongqing 400715, P.R. China

2Department of Neurosurgery, Research Institute of Surgery, Daping Hospital, Third Military Medical University, Chongqing 400042, P.R. China

Correspondence to:

Hongjuan Cui, e-mail: [email protected], [email protected]

Yundong Zhang, e-mail: [email protected]

Keywords: HDAC9, TAZ, cell cycle, EGFR, Glioblastoma

Received: December 8, 2014 Accepted: January 26, 2015 Published: February 10, 2015

ABSTRACT

Histone deacetylase 9 (HDAC9), a member of class II HDACs, regulates a wide variety of normal and abnormal physiological functions. We found that HDAC9 is over-expressed in prognostically poor glioblastoma patients. Knockdown HDAC9 decreased proliferation in vitro and tumor formation in vivo. HDAC9 accelerated cell cycle in part by potentiating the EGFR signaling pathway. Also, HDAC9 interacted with TAZ, a key downstream effector of Hippo pathway. Knockdown of HDAC9 decreased the expression of TAZ. We found that overexpressed TAZ in HDAC9-knockdown cells abrogated the effects induced by HDAC9 silencing both in vitro and in vivo. We demonstrated that HDAC9 promotes tumor formation of glioblastoma via TAZ-mediated EGFR pathway activation, and provide the evidence for promising target for the treatment of glioblastoma.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 3223

Publication Alerts

Research Papers:

HDAC9 promotes glioblastoma growth via TAZ-mediated EGFR pathway activation

Abstract